Chronic News and Research

RSS
Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

6 Dec 2010
Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

Updated Phase 1 study data of ponatinib in patients with refractory CML, Ph+ ALL presented at ASH

6 Dec 2010
Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

Research on BCR-ABL inhibitors for treating ALL, CML presented at ASH Annual Meeting

6 Dec 2010
Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

6 Dec 2010
Amgen announces final study results of Nplate in adults with chronic ITP

Amgen announces final study results of Nplate in adults with chronic ITP

6 Dec 2010
Research highlighting treatment for pediatric SCD, malaria presented at ASH 2010

Research highlighting treatment for pediatric SCD, malaria presented at ASH 2010

6 Dec 2010
BioCryst reports Phase 2 trial data of forodesine in patients with CLL

BioCryst reports Phase 2 trial data of forodesine in patients with CLL

6 Dec 2010
Ligand Pharmaceuticals reports preclinical study data on erythropoietin receptor agonists

Ligand Pharmaceuticals reports preclinical study data on erythropoietin receptor agonists

6 Dec 2010
Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

6 Dec 2010
Study compares efficacy of two treatments for iron overload caused by chronic transfusion therapy

Study compares efficacy of two treatments for iron overload caused by chronic transfusion therapy

6 Dec 2010
Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

6 Dec 2010
Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

6 Dec 2010
New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

6 Dec 2010
Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

Phase 2 survival data of sapacitabine in patients with MDS presented at ASH Annual Meeting

6 Dec 2010
Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

6 Dec 2010
New drug for non-Hodgkin’s lymphoma shows promise

New drug for non-Hodgkin’s lymphoma shows promise

5 Dec 2010
Appropriate level of Static Magnetic Field exposure for wound patients needs to be considered

Appropriate level of Static Magnetic Field exposure for wound patients needs to be considered

4 Dec 2010
Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

4 Dec 2010
Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

Pharnext receives French approval for Pleodrug Phase II clinical trial in Charcot-Marie Tooth disease type 1A

4 Dec 2010
Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

Pfizer plans regulatory submissions of bosutinib for CML based on BELA study

4 Dec 2010

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback